(Q55013304)

Alessandro Morabito

13

0 references

Nicola Normanno

Nicola Normanno

10

0 references

Gaetano Rocco

Gaetano Rocco

11

0 references

Massimo Di Maio

Massimo Di Maio

6

0 references

Maria Carmela Piccirillo

5

Maria Carmela Piccirillo

0 references

Raffaele Costanzo

3

Raffaele Costanzo

0 references

Agnese Montanino

2

Agnese Montanino

0 references

Claudia Sandomenico

4

Claudia Sandomenico

0 references

author name string

Guido Carillio

1

0 references

Pasqualina Giordano

8

0 references

Jane Bryce

9

0 references

Francesco Perrone

Expert Review of Anticancer Therapy

12

0 references

publication date

February 2012

0 references

published in

0 references

volume

12

0 references

issue

2

0 references

page(s)

163-175

0 references

cites work

EGFR antagonists in cancer treatment

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

Methodology of clinical trials with new molecular-targeted agents: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

Influence of unrecognized molecular heterogeneity on randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178

A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.178